US EditionAurobindo Pharma Leads Charge in Global HIV Treatment Expansion
GLOBAL (133 COUNTRIES), JUL 14 – The expanded license enables generic manufacturers to supply long-acting injectable HIV treatment in 133 countries, supporting WHO recommendations to improve treatment adherence.
- On Tuesday, Aurobindo Pharma announced that it will manufacture and distribute a long-acting injectable form of cabotegravir for HIV therapy across 133 nations.
- An update has been made to the licensing arrangement between ViiV Healthcare and the Medicines Patent Pool, allowing the use of CAB LA to be expanded from solely prevention to also include treatment, in alignment with the latest guidance from the World Health Organization.
- Aurobindo, together with Cipla and Viatris, is authorized to produce and distribute generic versions of long-acting cabotegravir combined with rilpivirine for treating HIV-1 in adults and adolescents, pending necessary regulatory clearances.
- Aurobindo Pharma Vice Chairman K Nithyananda Reddy expressed the company's honor in participating in the expanded licensing agreement with MPP and ViiV, highlighting their dedication to making this long-acting HIV treatment more accessible and affordable.
- This expanded access offers a vital treatment option with bi-monthly injections, improving adherence and reflecting progress toward increasing access in low- and middle-income countries.
Insights by Ground AI
Does this summary seem wrong?
12 Articles
12 Articles
Aurobindo Pharma to manufacture, supply HIV treatment cabotegravir across 133 countries
New Delhi: Hyderabad-based drugmaker Aurobindo Pharma will produce and supply Cabotegravir, a long-acting injectable HIV treatment, across 133 countries, including several low and middle-income...
·New Delhi, India
Read Full Article
Aurobindo Pharma Leads Charge in Global HIV Treatment Expansion
Aurobindo Pharma will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. As part of an expanded licensing agreement with the Medicines Patent Pool and ViiV Healthcare, this initiative will extend access to low and middle-income markets, promoting advanced HIV treatment alternatives.
·India
Read Full Article
Coverage Details
Total News Sources12
Leaning Left2Leaning Right1Center3Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 33%
C 50%
R 17%
Factuality
To view factuality data please Upgrade to Premium
